Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in rec...
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
About this item
Full title
Author / Creator
Chalker, Cameron , Voutsinas, Jenna M. , Wu, Qian Vicky , Santana‐Davila, Rafael , Hwang, Victoria , Baik, Christina S. , Lee, Sylvia , Barber, Brittany , Futran, Neal D. , Houlton, Jeffrey J. , Laramore, George E. , Liao, Jay Justin , Parvathaneni, Upendra , Martins, Renato G. , Eaton, Keith D. and Rodriguez, Cristina P.
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance status (PS) ≥2; the benefit of ICI in this population is therefore unknown.
Methods
We retrospectively rev...
Alternative Titles
Full title
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_53da6a9d3e554131937be881d3ebe09e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_53da6a9d3e554131937be881d3ebe09e
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.4722
